DURAK, A. Et Al. 2020. Titin and CK2 alpha are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats. CARDIOVASCULAR DRUGS AND THERAPY , vol.34, no.4 , 487-501.

DURAK, A., Bitirim, C. V., & Turan, B., (2020). Titin and CK2 alpha are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats. CARDIOVASCULAR DRUGS AND THERAPY , vol.34, no.4, 487-501.

DURAK, AYŞEGÜL, CEYLAN VERDA BİTİRİM, And Belma Turan. "Titin and CK2 alpha are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats," CARDIOVASCULAR DRUGS AND THERAPY , vol.34, no.4, 487-501, 2020

DURAK, AYŞEGÜL Et Al. "Titin and CK2 alpha are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats." CARDIOVASCULAR DRUGS AND THERAPY , vol.34, no.4, pp.487-501, 2020

DURAK, A. Bitirim, C. V. And Turan, B. (2020) . "Titin and CK2 alpha are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats." CARDIOVASCULAR DRUGS AND THERAPY , vol.34, no.4, pp.487-501.

@article{article, author={AYŞEGÜL DURAK Et Al. }, title={Titin and CK2 alpha are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats}, journal={CARDIOVASCULAR DRUGS AND THERAPY}, year=2020, pages={487-501} }